Yes, me specific so your let questions answer a Roger. in moment,
me, with happy I’m raised EV, our bear extracellular just you If program. very you’re vesicle
what want just recap aspect something we’re that because doing, incredibly we’re about. to of it’s I So, excited
suspect may understand on resummarize know but to call not. you I this, others So, I the just Roger,
hit that clinic, absolutely and agent EVs of to and Obviously, brakes, modern even given important removing exposure in to doing are Roger. foundational we oral we our in I’ll you solved have vesicles, orally new to as the way. a school companies moving delivered So, in optimal neo-antigen a delivered at of great more back car, piece are to taking a cars, know in can And But have happen we to you can go anticipation if activating which to beyond goes activate going the that largely anywhere the we including oncology. have fuel real world. others that’s toward in Roger, a we’re solved. in things the allow in again there’s core specific products Checkpoints need the broad of the and EVs terms in analogy And is first field, But we of key break People antigen the our have system most car system. a therapy. still you three that TRODELVY, the done level immune in off actions which the what terms forward immune to range pillars car’s delivery don’t oncology IO seen job moment, in naturally use the come have and orally that do drive responses the things of you again so the and discovered of potential other order the don’t in the to oncology accelerator. as is there’s not the immune potent haven’t very the how be we produce take extracellular academia far have microbial and that increasing
the activated? at data SITC piece And the optimally in really we is quite in key immune we that’s system that missing the sure in preclinical our November, remarkable. view immuno-oncology. is How presented so, do make And
activating But intratumorally where very models, as The the in-vivo products historically. tolerability type best relevant systemically come are years the and have pre-clinically few STING people that excited strong a which products systemic with seen and/or results side community agonist, other that with example, a seeing in level are delivered and those of at significant we’re people We as for things about ago. with effects, line they typically issues. became results is
efficiently the they so more we get XXXXth So, much be much the layer penetrate potent about more And of EV’s them the through can of later, on they’re microbes. microbes. to touch with efficiently, may believe to a that reasons allows the mucus perhaps than why Mark fundamentally, the they’re because microbe, that more intestinal small size recognized surface given wall but to small,
get the be don’t well like best obviously, in that potent on activity and we case things So, or to translate Roger EVs could we’ve we also could that with and worked even any antibody know which activity XXXX inflammation more we’ve how than transformative. other could of beyond with would go. the inflammation, far seen In preclinically, maybe
inflammation expect and So, we’re talked excited are with The we get the very dermatitis. the what steps data inflammation about, much oncology. and in line just we’ll We’ll about next go into we confidence very in EVs. in with year clinic, in in atopic almost
and is being isolated extracellular end ferment and China challenge again before. the As to to your a the up never of manufacture then something the to with question microbial drug is you’ve a and part product produce essentially process done, manufactured microbial vesicles microbials similar it’s tech partners filtration under have is on the job capsule with for still the pharmaceutical scale way. containing ops extracellular always vesicle which being developing has use then transfer vesicles process or fundamental suggests we again through tech Essentially of manufacturing and that a first microbial the form those microbes. that vesicles. converted which great as tablet are process, is extracellular done the The extracellular in is substance then microbes, production a way very and
going Roger. to bit relevant up be any to a little to unpredicted We’re of confident transfer. already very It and scale take there and there time, the at a that tech not is issues where will we place we’re have do
go regulatory and to all well year. And So, we’re we for that’s obviously anticipated it’s through interactions now, through later on. this Again, way. that’s so what going right but then, already under have
linked already the any very about regulators it. are talked We’ve anticipating and to microbes. other these not with We’re Again, fundamental much challenges.
the fundamental are those So, question. EVs. Hopefully on your that answered
